Form Type: 4

SEC EDGAR Link
Accession Number:0001562180-21-004339
Date:2021-06-15
Issuer: SAGE THERAPEUTICS, INC. (SAGE)
Original Submission Date:

Reporting Person:

ROBICHAUD ALBERT
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET CAMBRIDGE, MA 02142

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-06-15 A 4,000 a $0.00 140,795 direct
COMMON STOCK 2021-06-15 F 1,144 d $58.80 139,651 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 on march 25, 2020, the reporting person was granted performance stock units (psu) to acquire a total of 10,000 shares of common stock. the psu vests upon the achievement of certain milestones, one of which was met on june 15, 2021, resulting in the vesting of the psu as to 4,000 shares.
f2 reflects beneficial ownership balance, which includes 54 shares purchased on december 31, 2019 under the sage therapeutics, inc. 2014 employee stock purchase plan (the "espp") and 341 shares purchased on june 30, 2020 under the espp.

Elevate your investments